---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-030033"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-06-25T12:00:40+00:00"
generated_at: "2026-06-25T12:05:52.394941+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharma reports preclinical data showing Mira-55 differentiated from THC, anxiolytic effect

## Summary
- Mira-55 did not produce THC-like locomotor suppression or catalepsy in standard preclinical assays.
- Modest body temperature reduction from Mira-55 was not reversed by CB1 antagonist rimonabant, indicating distinct mechanism.
- Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity of rimonabant; THC showed no anxiolysis.
- Data builds on March 2026 results; company advancing Mira-55 toward IND for chronic inflammatory pain.
- No psychoactivity or CNS side effects observed; candidate designed to avoid THC liabilities.

## SEC filing metadata
- accession: 0001493152-26-030033
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-06-25T12:00:40+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/0001493152-26-030033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-030033
- JSON: https://secwatch.observer/filing/0001493152-26-030033.json
- Plain text: https://secwatch.observer/filing/0001493152-26-030033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.